: Benralizumab improves outcomes in severe eosinophilic asthma patients regardless of smoking history, with former smokers achieving similar benefits in exacerbation reduction, oral corticosteroid sparing, asthma control and lung function to never-smokers https://bit.ly/4grFy7e.
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study / Senna, Gianenrico; Brussino, Luisa; Aliani, Maria; Altieri, Elena; Bracciale, Pietro; Caiaffa, Maria Filomena; Cameli, Paolo; Canonica, Giorgio Walter; Caruso, Cristiano; Centanni, Stefano; De Michele, Fausto; Del Giacco, Stefano; Di Marco, Fabiano; Malerba, Laura; Menzella, Francesco; Pelaia, Girolamo; Rogliani, Paola; Romagnoli, Micaela; Schino, Pietro; Schroeder, Jan Walter; Vultaggio, Alessandra; D'Amato, Maria; Caminati, Marco. - In: ERJ OPEN RESEARCH. - ISSN 2312-0541. - ELETTRONICO. - 12:(2026), pp. 00881-2025.1-00881-2025.4. [10.1183/23120541.00881-2025]
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study
Cameli, Paolo;Centanni, Stefano;Vultaggio, Alessandra;
2026
Abstract
: Benralizumab improves outcomes in severe eosinophilic asthma patients regardless of smoking history, with former smokers achieving similar benefits in exacerbation reduction, oral corticosteroid sparing, asthma control and lung function to never-smokers https://bit.ly/4grFy7e.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Former smoker status_ANANKE.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
622.97 kB
Formato
Adobe PDF
|
622.97 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
